001     142871
005     20240229112532.0
024 7 _ |a 10.1136/gutjnl-2017-314828
|2 doi
024 7 _ |a pmid:29158237
|2 pmid
024 7 _ |a 0017-5749
|2 ISSN
024 7 _ |a 1468-3288
|2 ISSN
024 7 _ |a altmetric:29388632
|2 altmetric
037 _ _ |a DKFZ-2019-00501
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Huang, Lei
|0 P:(DE-He78)448ff49e51672d79b4747339ac15c898
|b 0
|e First author
|u dkfz
245 _ _ |a Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations.
260 _ _ |a London
|c 2019
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661347255_8349
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Resection can potentially cure resectable pancreatic cancer (PaC) and significantly prolong survival in some patients. This large-scale international study aimed to investigate variations in resection for PaC in Europe and USA and determinants for its utilisation.Data from six European population-based cancer registries and the US Surveillance, Epidemiology, and End Results Program database during 2003-2016 were analysed. Age-standardised resection rates for overall and stage I-II PaCs were computed. Associations between resection and demographic and clinical parameters were assessed using multivariable logistic regression models.A total of 153 698 records were analysed. In population-based registries in 2012-2014, resection rates ranged from 13.2% (Estonia) to 21.2% (Slovenia) overall and from 34.8% (Norway) to 68.7% (Denmark) for stage I-II tumours, with great international variations. During 2003-2014, resection rates only increased in USA, the Netherlands and Denmark. Resection was significantly less frequently performed with more advanced tumour stage (ORs for stage III and IV versus stage I-II tumours: 0.05-0.18 and 0.01-0.06 across countries) and increasing age (ORs for patients 70-79 and ≥80 versus those <60 years: 0.37-0.63 and 0.03-0.16 across countries). Patients with advanced-stage tumours (stage III-IV: 63.8%-81.2%) and at older ages (≥70 years: 52.6%-59.5%) receiving less frequently resection comprised the majority of diagnosed cases. Patient performance status, tumour location and size were also associated with resection application.Rates of PaC resection remain low in Europe and USA with great international variations. Further studies are warranted to explore reasons for these variations.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Jansen, Lina
|0 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
|b 1
|u dkfz
700 1 _ |a Balavarca, Yesilda
|0 P:(DE-He78)48988e4552476bf82978f0e1ac8a4cf0
|b 2
|u dkfz
700 1 _ |a Molina-Montes, Esther
|b 3
700 1 _ |a Babaei, Masoud
|0 P:(DE-He78)b16bd486ec798cca3184e838e7f49ac4
|b 4
|u dkfz
700 1 _ |a van der Geest, Lydia
|b 5
700 1 _ |a Lemmens, Valery
|b 6
700 1 _ |a Van Eycken, Liesbet
|b 7
700 1 _ |a De Schutter, Harlinde
|b 8
700 1 _ |a Johannesen, Tom B
|b 9
700 1 _ |a Fristrup, Claus W
|b 10
700 1 _ |a Mortensen, Michael B
|b 11
700 1 _ |a Primic-Žakelj, Maja
|b 12
700 1 _ |a Zadnik, Vesna
|b 13
700 1 _ |a Becker, Nikolaus
|0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
|b 14
|u dkfz
700 1 _ |a Hackert, Thilo
|b 15
700 1 _ |a Mägi, Margit
|b 16
700 1 _ |a Cassetti, Tiziana
|b 17
700 1 _ |a Sassatelli, Romano
|b 18
700 1 _ |a Grützmann, Robert
|b 19
700 1 _ |a Merkel, Susanne
|b 20
700 1 _ |a Gonçalves, Ana F
|b 21
700 1 _ |a Bento, Maria J
|b 22
700 1 _ |a Hegyi, Péter
|b 23
700 1 _ |a Lakatos, Gábor
|b 24
700 1 _ |a Szentesi, Andrea
|b 25
700 1 _ |a Moreau, Michel
|b 26
700 1 _ |a van de Velde, Tony
|b 27
700 1 _ |a Broeks, Annegien
|b 28
700 1 _ |a Sant, Milena
|b 29
700 1 _ |a Minicozzi, Pamela
|b 30
700 1 _ |a Mazzaferro, Vincenzo
|b 31
700 1 _ |a Real, Francisco X
|b 32
700 1 _ |a Carrato, Alfredo
|b 33
700 1 _ |a Molero, Xavier
|b 34
700 1 _ |a Besselink, Marc G
|b 35
700 1 _ |a Malats, Núria
|b 36
700 1 _ |a Büchler, Markus W
|b 37
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 38
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 39
|e Last author
|u dkfz
773 _ _ |a 10.1136/gutjnl-2017-314828
|g Vol. 68, no. 1, p. 130 - 139
|0 PERI:(DE-600)1492637-4
|n 1
|p 130 - 139
|t Gut
|v 68
|y 2019
|x 1468-3288
909 C O |p VDB
|o oai:inrepo02.dkfz.de:142871
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)448ff49e51672d79b4747339ac15c898
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)48988e4552476bf82978f0e1ac8a4cf0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)b16bd486ec798cca3184e838e7f49ac4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 38
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 39
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2019
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GUT : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b GUT : 2017
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21